Journal Watch

  • PDF / 165,729 Bytes
  • 11 Pages / 612.28 x 790.87 pts Page_size
  • 22 Downloads / 220 Views

DOWNLOAD

REPORT


Mol Diagn Ther 2011; 15 (6): 361-371 1177-1062/11/0006-0361/$49.95/0

ª 2011 Adis Data Information BV. All rights reserved.

Journal Watchy

Contents 1. Highlights from Adis Journals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361 1.1 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361 1.2 Cardiovascular Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364 1.3 Immunologic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365 1.4 Neurologic and Psychiatric Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367 1.5 Drug Development and Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368 2. News from Other Sources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369 2.1 Cost Effectiveness of Diagnostic Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369 2.2 Pharmacogenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370

1. Highlights from Adis Journals

outcomes of the commonly used ‘7+3’ regimen of an anthracycline plus cytarabine with daunorubicin, which is clearly an ineffective therapy in the majority of patients.

1.1 Cancer Acute Myeloid Leukemia: Optimal Management and

Villela L, Bolan˜os-Meade J. Acute myeloid leukaemia: optimal management and recent developments. Drugs 2011; 71 (12): 1537-50

Recent Developments

The current treatment of patients with acute myeloid leukemia yields poor results, with expected cure rates in the order of 30–40%, depending on the biologic characteristics of the leukemic clone. Therefore, new agents and schemas are intensively studied in order to improve patient outcomes. This review summarizes some of these new paradigms, including new questions such as which anthracycline is most effective and at what dose. High doses of daunorubicin have shown better responses in young patients and are well tolerated in elderly patients. Monoclonal antibodies are promising agents in goodrisk patients. Drugs blocking signaling pathways could be used in combination with

Data Loading...